Phase 4 N=78 A Placebo-Controlled Study of Mirtazapine for PTSD
Anxiety · PTSD
Primary: Structured Interview of Posttraumatic Stress Disorder (SIP) — -7.61; -5.83 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=108 Sitagliptin in Combination With Metformin and Sulfonylurea
Type 2 Diabetes Mellitus
Primary: Hemoglobin A1c (HbA1c) Change From Baseline — -1.3 percentage
Phase 4 N=126 Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
Nicotine Dependence
Primary: Changes in Log Brain-wave (EEG) Activity (Power [Microvolts Squared]) From Pre-quit Baseline to 66 Days Post-quit, Assessed at 3, 24, 45, and 66 Days Post-quit. — .055…
Phase 4 N=283 Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit
Hypothyroidism
Primary: Number of Participants With Positive and Negative TSH Test Result — 103; 179; 121; 162 Participants
Phase 4 N=20 Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Hypertension
Primary: Prescription Rates — 80; 100 % new thiazide prescriptions
Phase 4 N=34 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
Dysthymic Disorder
Primary: Hamilton-Depression Rating Scale (HDRS-24 Items) — 10.88; 16.41 units on a scale — p=0.10
Phase 4 N=18 Wellbutrin XL for Dysthymic Disorder
Dysthymic Disorder
Primary: Hamilton Depression Rating Scale, 24 Items (HDRS) — 14.4; 13.3 units on a scale — p=<.05
Phase 4 N=221 Metformin Versus Insulin in Gestational Diabetes
Gestational Diabetes
Primary: Birth Weight Per Arm — 3604; 3589 g
Phase 4 N=138 Effect of Rowachol on Prevention of Postcholecystectomy Syndrome
Postcholecystectomy Syndrome
Primary: the Number of the Participants Have Postoperative RUQ Pain — 3; 9 number of participants
Phase 4 N=195 Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients
Hyperglycemia · Acute Coronary Syndromes · Myocardial Infarction
Primary: Median Glucose Values From Steady State Through 48 Hours or Until Discharge. — 132; 127; 105 mg/dL — p=<0.001
Phase 4 N=80 Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block
Fracture of Ankle
Primary: Quality of Recovery — 181; 184; 181 units on a scale
Phase 4 N=190 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
Atrial Fibrillation
Primary: Documented Recurrence of Atrial Fibrillation/Atrial Flutter — 59; 47 percentage of participants
Phase 4 N=36 Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
Hypertension · Type 2 Diabetes Mellitus
Primary: Flow Mediated Dilation — 6.2; 4.1 percentage of change in dilation
Phase 4 N=224 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Relapsing Remitting Multiple Sclerosis (RRMS)
Primary: Change From Baseline in the Timed 100-meter Walk Test (T100T) — 86.0; -1.2; -1.6 seconds — p=0.0003
Phase 4 N=41 Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Brief Pain Inventory (BPI) Change — 5.2; 5.6; 4.9; 4.8 units on a scale — p=0.42